Cardio3 BioSciences to Present at the Alliance for Regenerative Medicine Stem Cell Meeting on the Mesa 7-9 October 2014, La Jolla, San Diego, CA

Cardio3 Biosciences (Paris:CARD) (Brussels:CARD) (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery, development and commercialization of regenerative, protective and reconstructive therapies, announces today its presence to the prestigious Alliance for Regenerative Medicine Stem Cell Meeting on the Mesa, a reference in the cell therapy industry, which will be held from 7 to 9 October in San Diego, CA, USA.

The Alliance for Regenerative Medicine (ARM) - the leading global advocacy organization in the field of regenerative medicine - the California Institute for Regenerative Medicine (CIRM) and the Sanford Consortium for Regenerative Medicine, are organizing the 2014 Stem Cell Meeting on the Mesa, a three-day event gathering senior executives, top decision makers in the regenerative medicine industry and the scientific community to advance cutting-edge research into cures.

Cardio3 BioSciences’ CEO Christian Homsy will present at the opening plenary session on 7 October and at the partnering forum on 8 October (see detailed agenda below). This partnering forum is the unique partnering meeting of its kind dedicated solely to facilitating connections for the regenerative medicine and advanced therapies industry.

• Tuesday 7 October, 8:15 AM (Pacific Time) - Cardio3 BioSciences’ CEO Christian Homsy will participate in the plenary session on "Cell Therapy product development”
• Wednesday 8 October 4:15PM (Pacific Time) – Cardio3 BioSciences’ CEO Christian Homsy will present Cardio3 BioSciences’ business strategy and current projects.

*** END ***

Follow us on Twitter @Cardio3Bio.

About the Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine and advanced therapies. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, DC to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 150 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit www.alliancerm.org.

About Cardio3 BioSciences
Cardio3 BioSciences is a Belgian leading biotechnology company focused on the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases. The company was founded in 2007 and is based in the Walloon region of Belgium. Cardio3 BioSciences leverages research collaborations in the US and in Europe with Mayo Clinic and the Cardiovascular Centre Aalst, Belgium.
The Company’s lead product candidate C-Cure® is an innovative pharmaceutical product that is being developed for heart failure indication. C-Cure® consists of a patient’s own cells that are harvested from the patient’s bone marrow and engineered to become new heart muscle. This process is known as Cardiopoiesis.
Cardio3 BioSciences has also developed C-Cath®_ez, the most technologically advanced injection catheter with superior efficiency of delivery of bio therapeutic agents into the myocardium.
Cardio3 BioSciences’ shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CARD.

C3BS-CQR-1, C-Cure, C-Cath, Cardio3 BioSciences and the Cardio3 BioSciences and C-Cath logos are trademarks or registered trademarks of Cardio3 BioSciences SA, in Belgium, other countries, or both. Mayo Clinic holds equity in Cardio3 BioSciences as a result of intellectual property licensed to the company. In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of required Phase III studies; additional clinical results validating the use of adult autologous stem cells to treat heart failure; satisfaction of regulatory and other requirements; and actions of regulatory bodies and other governmental authorities.